ANGO - AngioDynamics, Inc.
| Previous Close | 20.45 |
| Open | 20.06 |
| Bid | 19.99 x 100 |
| Ask | 19.99 x 300 |
| Day's Range | 19.90 - 20.17 |
| 52 Week Range | 14.80 - 20.71 |
| Volume | 203,854 |
| Avg. Volume | 258,585 |
| Market Cap | 734.618M |
| Beta | 0.71 |
| PE Ratio (TTM) | 554.44 |
| EPS (TTM) | 0.04 |
| Earnings Date | Jul 16, 2018 - Jul 20, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.00 |
- Business Wire•10 days ago
AngioDynamics to Present at Two Investor Conferences in May
AngioDynamics, Inc. , a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, surgery and oncology, tod
- ACCESSWIRE•15 days ago
Blog Exposure - Waters Corp. to Significantly Expand its Precision Chemistry Facility in Massachusetts
Stock Monitor: AngioDynamics Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 05, 2018 / Active-Investors.com has just released a free research report on Waters Corp. (NYSE: WAT). If you want access ...
- GlobeNewswire•16 days ago
Recent Analysis Shows Multi-Color, Madrigal Pharmaceuticals, SPX, AngioDynamics, Atara Biotherapeutics, and Quanex Building Products Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, April 04, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- Zacks•17 days ago
AngioDynamics (ANGO) Product Line Strong, Debt Level High
AngioDynamics (ANGO) rides on promising NanoKnife performance. Dwindling sales are a concern.
- Zacks•18 days ago
AngioDynamics (ANGO) Beats on Q3 Earnings, Reiterates View
AngioDynamics (ANGO) witnesses gross margin expansion and strong profits in the third quarter of fiscal 2018. However, lower sales in the company's RFA product line in Japan is a concern.
Motley Fool•19 days agoAngioDynamics (ANGO) Q3 2018 Earnings Conference Call Transcript
ANGO earnings call for the period ending February 28, 2018.
- Thomson Reuters StreetEvents•22 days ago
Edited Transcript of ANGO earnings conference call or presentation 29-Mar-18 12:00pm GMT
Q3 2018 AngioDynamics Inc Earnings Call
- Simply Wall St.•22 days ago
Where AngioDynamics Inc (NASDAQ:ANGO) Stands In Earnings Growth Against Its Industry
For investors with a long-term horizon, examining earnings trend over time and against industry peers is more insightful than looking at an earnings announcement in one point in time. InvestorsRead More...
- Associated Press•22 days ago
AngioDynamics misses 3Q revenue forecasts
The Latham, New York-based company said it had net income of 37 cents per share. Earnings, adjusted for one-time gains and costs, were 25 cents per share. The medical device maker posted revenue of $83.9 ...
- Business Wire•22 days ago
AngioDynamics Reports Fiscal 2018 Third Quarter Financial Results
AngioDynamics, Inc. , a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, surgery and oncology, today announced financial results for the third quarter of fiscal year 2018, which ended February 28, 2018.
- ACCESSWIRE•22 days ago
AngioDynamics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 29, 2018 / AngioDynamics, Inc. (NASDAQ: ANGO ) will be discussing their earnings results in their Q3 Earnings Call to be held on March 29, 2018 at 8:00 AM Eastern Time. ...
- Business Wire•last month
AngioDynamics to Present at the Needham 17th Annual Healthcare Conference
AngioDynamics, Inc. , a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, surgery and oncology, today announced that Michael C.
Market Realist•2 months agoAnalysts’ Ratings for Abaxis and Its Peers in February 2018
Incorporated in California, Abaxis (ABAX) develops, manufactures, and commercializes portable blood analysis systems that are used in a wide range of medical specialties in human or veterinary patient care. The company has worldwide operations and operates in two business segments: the medical market and the veterinary market. Of the ten analysts covering Abaxis in February 2018, two analysts gave the stock “strong buy” ratings, six gave it “hold” ratings, and two gave it “sell” ratings.
Market Realist•2 months agoA Look at the Performances of Abaxis’s Product Categories
What's Keeping Abaxis on Investors' Radar in 2018?
- Business Wire•2 months ago
AngioDynamics to Report Fiscal 2018 Third Quarter Financial Results on March 29, 2018
AngioDynamics, Inc. , a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, surgery and oncology, today announced that it will report financial results for the third quarter of fiscal year 2018 before the market open on Thursday, March 29, 2018.
- Business Wire•2 months ago
AngioDynamics to Present at the Barclays Global Healthcare Conference
AngioDynamics, Inc. , a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, surgery and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, and Michael C.
- GlobeNewswire•2 months ago
Investor Expectations to Drive Momentum within Regal Beloit, Kaiser Aluminum, AngioDynamics, Mulesoft, Assembly Biosciences, and Woodward — Discovering Underlying Factors of Influence
NEW YORK, Feb. 06, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Regal ...
- Zacks•3 months ago
AngioDynamics Receives FDA Nod, to Treat Pancreatic Cancer
AngioDynamics (ANGO) gets flagship NanoKnife designated with EAP.
- ACCESSWIRE•3 months ago
Free Post Earnings Research Report: Waters’ Sales Jumped 9%; Adjusted EPS Surged 14%
Stock Monitor: AngioDynamics Post Earnings Reporting LONDON, UK / ACCESSWIRE / January 25, 2018 / Active-Investors.com has just released a free earnings report on Waters Corp. (NYSE: WAT ). If you want ...
- Business Wire•3 months ago
AngioDynamics Receives FDA Expedited Access Pathway Designation for the NanoKnife® System for the Treatment of Stage III Pancreatic Cancer
AngioDynamics, Inc. , a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, surgery and oncology, today announced that the United States Food and Drug Administration has granted the Expedited Access Pathway designation to the Company’s NanoKnife® System and proposed indication for use for the treatment of Stage III pancreatic cancer....
- Zacks•3 months ago
AngioDynamics (ANGO) Banks on Buyouts, Debt Level High
AngioDynamics (ANGO) continues to expand its business on the back of acquisitions and strategic alliances.
- Zacks•3 months ago
Zacks.com featured highlights include: AngioDynamics, Zumiez, GP Strategies, AngloGold and Raymond James
Zacks.com featured highlights include: AngioDynamics, Zumiez, GP Strategies, AngloGold and Raymond James
- Zacks•3 months ago
Bet on These 5 PEG-Ratio Based GARP Picks
A lower PEG ratio, preferably less than one, is always better for GARP investors.
- Zacks•3 months ago
AngioDynamics (ANGO) Misses on Earnings, Revenues in Q2
Dwindling revenues in two major segments hurt AngioDynamics' (ANGO) second-quarter results.
